RT Journal Article
T1 Anaphylaxis to 2 NSAIDs in a Patient Who Tolerated ASA.
A1 Bogas, G
A1 Perez-Sanchez, N
A1 Andreu, I
A1 Doña, I
A1 Perkins, J R
A1 Blanca, M
A1 Canto, G
A1 Cornejo-Garcia, J A
A1 Blanca-Lopez, N
K1 ASA tolerance
K1 Anaphylaxis
K1 Cross-intolerance
K1 NSAID hypersensitivity
K1 Selective reactions
K1 Hipersensibilidad a AINE
K1 Intolerancia cruzada
K1 Reacciones selectivas
K1 Anafilaxia
K1 Tolerancia a AAS
AB Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most frequent cause of drug hypersensitivity [1]. NSAID-induced reactions can be classified into 5 categories: (1) NSAID-exacerbated respiratory disease (NERD); (2) NSAID-exacerbated cutaneous disease (NECD); (3) NSAID-induced urticaria and/or angioedema (NIUA); (4) single NSAID-induced  urticaria/angioedema/anaphylaxis (SNIUAA); and (5) single NSAID-induced delayed hypersensitivity reactions (SNIDR) [2]. Patients in the first 3 categories react to NSAIDs from various chemical groups in a nonallergic type of drug hypersensitivity known as cross-intolerance. The mechanism involved in these reactions is thought to be related to an imbalance in the arachidonic acid metabolic pathway leading to increased release of cysteinyl leukotrienes.
PB Esmon Publicidad
SN 1018-9068
YR 2016
FD 2016
LK http://hdl.handle.net/10668/10312
UL http://hdl.handle.net/10668/10312
LA en
NO Bogas G, Pérez-Sánchez N, Andreu I, Doña I, Perkins JR, Blanca M, et al. Anaphylaxis to 2 NSAIDs in a Patient Who Tolerated ASA. J Investig Allergol Clin Immunol. 2016;26(4):266-8
NO JA Cornejo-García is funded by the Miguel Servet Program (Ref CP14/00034) and JR Perkins by the Sara Borrell Program (Ref CD14/00242) (Carlos III National Health Institute, Spanish Ministry of Economy and Competitiveness). This study was supported by grants from the Carlos III National Health Institute RD12/0013 (RIRAAF network), FIS (PI12/02247, PI13/02598, and PI15/00726), and the Andalusian Health Service (PI-0279-2012). This work was supported by grants from the European Regional Development’s Funds (FEDER).
DS RISalud
RD Apr 9, 2025